GSK applies to expand RSV vaccine use to adults 18 and up in EU

GSK has announced that the European Medicines Agency (EMA) has accepted its application to broaden the use of its Arexvy RSV vaccine to include adults aged 18 and over, with a decision expected in the first half of 2026. Currently approved for specific age groups within the EU, Arexvy's expanded approval would make it available to a significantly larger adult population, potentially boosting GSK's revenue stream from the vaccine.

Analysis

GSK has formally submitted an application to the European Medicines Agency (EMA) seeking to expand the approved use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to include adults aged 18 years and older. A regulatory decision on this application is anticipated in the first half of 2026. Currently, Arexvy is approved for specific age groups in the European Union, and this expansion, if granted, would significantly broaden the vaccine's addressable adult market. This development is viewed with mildly positive sentiment (score 0.3) and is assessed to have a low immediate market impact, consistent with the extended timeline for the EMA's decision. While the potential market expansion for Arexvy represents a positive pipeline development, the article also references an InvestingPro AI analysis which did not identify GSK as a top-tier undervalued stock, suggesting a more nuanced valuation perspective.

Key Decisions for Investors

• Investors should monitor the EMA's review process for Arexvy's label expansion, as a positive decision in H1 2026 could enhance GSK's long-term revenue from its vaccine portfolio.
• Given the 2026 timeline for the EMA's decision, any financial contribution from this expanded indication for Arexvy is a medium-term consideration, not an immediate earnings driver.
• This specific positive development regarding Arexvy should be weighed against broader company valuation metrics and market positioning, especially in light of external analyses suggesting GSK may not be deeply undervalued.